Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 593 results for "pfizer"

Retail Report Card: Consumers Give Retailers a Grade of C/D for Mobile Technology
SPi World News

Update: Ligand Wins EU Approval For Duavive

Summary On Friday, Ligand's partner, Pfizer, announced the EU approval for Duavive. I reiterate my bull thesis on Ligand. As expected, Ligand continues to enhance its growth through its royalty-based portfolio of assets. A few months ago, I ... Seeking Alpha, 5 hours ago

411 images for pfizer

WKRB News, 1 day ago
Yahoo! News Australia, 1 day ago
Bidness Etc, 2 days ago
BBC, 10 hours ago
La Jolla Patch, 1 day ago
Pharmafocus, 2 days ago
Silicon Republic, 5 days ago
Groton Patch, 2 days ago
Irish Times, 5 days ago
Pharmaceutical Business Review, 3 days ago
Reuters UK

New Pfizer bid unlikely says AstraZeneca CEO

s Editor "I consider it unlikely that Pfizer (NYSE:PFE) will return with a bid," reports Swedish business daily Dagens Industri quoting AstraZeneca (NYSE:AZN) CEO Pascal Soriot. "I can't say it will never happen, but the probability that Pfizer ...
 Seeking Alpha8 hours ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI  4 Traders1 day ago

Pfizer Unlikely To Make New Bid For AstraZeneca: Swedish Newspaper

STOCKHOLM ( ) -- The American Pfizer Inc. is unlikely to come back with a fresh bid for the Anglo-Swedish AstraZeneca PLC, the latter's top executive was quoted as saying by the Swedish business daily Dagens Industri Saturday. A $118 billion offer ...
 International Business Times8 hours ago
Bidness Etc

Pfizer announces positive results from phase 3 study evaluating pregabalin CR formulation to treat postherpetic neuralgia patients

Pfizer announced top-line results from a double-blind phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in ...
 PharmaBiz1 day ago Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug  Bidness Etc2 days ago Pfizer starts phase 2 trial of PF-06252616 to treat patients with duchenne muscular dystrophy  PharmaBiz2 days ago Pfizer reports start of Phase 2 DMD study of PF-06252616  BusinessWeek3 days ago
Pharmaceutical Technology

Pfizer To Develop GHD Drug With OPKO Health

By Estel Grace Masangkay Pfizer announced it has partnered with Miami-based OPKO Health to develop the latter's long-acting hGH-CTP as treatment for growth hormone deficiency (GHD) syndrome in both adults and children, as well as for growth ...
 Bioresearch Online3 days ago Opko, Pfizer sign pact to develop & commercialise long-acting hGH-CTP  PharmaBiz4 days ago Pfizer Ponies Up to Develop Long-acting Growth Hormone  TheStreet.com5 days ago Pfizer and OPKO collaborate to develop and commercialise hGH-CTP to treat GHD  Pharmaceutical Technology5 days ago

Pfizer (PFE) Trading Near $31.22 Support Level

After closing Thursday at $31.97, Pfizer Inc. ("PFE) presents an attractive opportunity to get a 3.37% return in just 182 days, which is an annualized return of 6.75% (for comparison purposes only).
 Individual.com2 days ago Pfizer (PFE) Showing Support Near $30.25  Individual.com3 days ago

Pfizer: Outcome of AGM

Pfizer Ltd has informed BSE that 63rd Annual General Meeting (AGM) of the Company was held on November 10, 2014
 Money Control3 days ago Pfizer: AGM on Nov 10, 2014  Money Control1 month ago
Seeking Alpha

Pfizer Is A Great Income Stock On A Pullback

Summary PFE's dividend has become far less attractive in recent years because of strong capital gains. Dividends and buybacks continue to boost shareholder returns and will for the foreseeable future. I like PFE but would prefer it around $28 ...
 Seeking Alpha3 days ago 7 Stocks Providing Their Shareholders A Growing Income With Higher Cash Dividends  Seeking Alpha1 day ago
Motley Fool

3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.

The largest pharmaceutical company in the world, Pfizer (NYSE: PFE However, there's one big problem with Pfizer: It's currently suffering from a monstrous patent cliff whereby some of its key drugs are losing their exclusivity and being exposed to ...
 Motley Fool2 days ago

Pfizer Set to Possibly Pullback After Yesterday's Rally of 2.73%

Pfizer (NYSE:PFE) traded in a range yesterday that spanned from a low of $31.42 to a high of $32.00. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $31.56 on volume of 35.7 million shares. Often times ...
 Individual.com2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less